Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either CSL Limited Sponsored ADR (CSLLY) or argenex SE (ARGX) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revis ...

Core Viewpoint - argenx SE is holding its Annual General Meeting on May 6, 2026, to discuss key agenda items including the adoption of the 2025 annual accounts and changes to the Board of Directors [1][3]. Meeting Details - The Annual General Meeting will take place at 13:00 CET at the Hilton Amsterdam Schiphol [1]. - Shareholders and other meeting rights holders are invited to attend, with details available on the argenx website [2]. Agenda Items - The agenda includes the discussion and adoption of the 2025 annual accounts, an advisory vote on the 2025 remuneration report, discharge of directors for their 2025 duties, and authorization for the Board to issue shares [3]. - Proposed changes to the Board include the retirement of Jim Daly as non-executive director and Chair of the Commercialization Committee, effective May 6, 2026 [3][4]. - The Board is currently exploring succession options for Jim Daly [3]. Board Appointments - Karen Massey is appointed as executive director for a term of 4 years [8]. - Tim Van Hauwermeiren is appointed as non-executive director for a term of 4 years [8]. - Ana Céspedes and Camilla Sylvest are re-appointed as non-executive directors for terms of 4 years [8]. - Pamela Klein is re-appointed as a non-executive director for a term of 2 years [8]. Company Overview - argenx is a global immunology company focused on severe autoimmune diseases, partnering with academic researchers to develop novel antibody-based medicines [6]. - The company has developed the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its potential in various serious autoimmune diseases [6].

Argenx SE (NASDAQ:ARGX) ranks among the best growth stocks to buy and hold for the long term. Following the company’s Q4 results, Oppenheimer increased its price target for Argenx SE (NASDAQ:ARGX) to $1,060 from $1,040 on February 26 while keeping an Outperform rating. The company reported earnings per share of $8.02, exceeding the projected $5.95. Revenue also came in slightly above expectations, totaling $1.29 billion vs $1.28 billion. According to Oppenheimer, Vyvgart’s total revenues for the fourth ...

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences across the company [1] - Elon Musk predicts that by 2040, humanoid robots could create a market worth $250 trillion, representing a major shift in the global economy driven by AI innovation [2][3] - Major firms like PwC and McKinsey acknowledge the multi-trillion-dollar potential of AI, suggesting a broad consensus on its economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is redefining work, learning, and creativity, leading to increased interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, with its technology posing a threat to competitors [4][6] - Prominent figures in technology and investment, including Bill Gates and Warren Buffett, recognize AI as a significant advancement with the potential for substantial social benefits [8]

Core Insights - Argenx SE will present data for VYVGART and pipeline candidates at the 2026 American Academy of Neurology Annual Meeting, highlighting advancements in treatments for severe autoimmune diseases [1][2] Group 1: VYVGART Developments - New Phase 3 results in ocular myasthenia gravis (oMG) will demonstrate VYVGART's potential as a targeted treatment option for patients [2][5] - Positive results from the Phase 3 ADAPT OCULUS study confirm VYVGART's therapeutic potential in adults with oMG, marking a significant advancement in treatment options [6] - Data from the ADAPT SERON study supports VYVGART's efficacy across broader patient populations, including generalized myasthenia gravis (gMG) patients without detectable anti-acetylcholine receptor antibodies [6][39] Group 2: Pipeline Candidates - Argenx will share results from the ARGX-119 Phase 1b trial evaluating adimanebart in patients with DOK7 congenital myasthenic syndromes, showing a favorable safety profile and functional improvements [4][39] - Empasiprubart, a novel monoclonal antibody, is being evaluated for multiple severe autoimmune indications, including chronic inflammatory demyelinating polyneuropathy (CIDP) [29] Group 3: CIDP Insights - Results from an ADHERE post hoc analysis will highlight VYVGART Hytrulo's impact in treatment-naïve CIDP patients, supporting its earlier use in treatment paradigms [3][39] - Real-world insights will illustrate physician approaches to transitioning patients from intravenous immunoglobulin to VYVGART Hytrulo, aiming to enhance patient outcomes [39] Group 4: Presentation Details - The presentations at the AAN Annual Meeting will include various studies on myasthenia gravis and CIDP, showcasing the breadth of research and data supporting VYVGART and its pipeline candidates [4][6][7]

Core Insights - Argenx SE will present data for VYVGART and pipeline candidates at the 2026 American Academy of Neurology Annual Meeting, highlighting advancements in treatments for severe autoimmune diseases [1][2][36] Group 1: VYVGART Developments - New Phase 3 results in ocular myasthenia gravis (oMG) will demonstrate VYVGART's potential as a targeted treatment option for patients [2][6] - Positive results from the Phase 3 ADAPT OCULUS study confirm VYVGART's therapeutic potential in adults with oMG, marking a significant advancement in treatment options [5][6] - Data from the ADAPT SERON study supports VYVGART's efficacy across broader patient populations, including generalized myasthenia gravis (gMG) patients without detectable anti-acetylcholine receptor antibodies [6][38] Group 2: Pipeline Candidates - Argenx will share results from the ARGX-119 Phase 1b trial evaluating adimanebart in patients with DOK7 congenital myasthenic syndromes, showing a favorable safety profile and functional improvements [4][38] - Empasiprubart is being evaluated for multiple severe autoimmune indications, including chronic inflammatory demyelinating polyneuropathy (CIDP) and delayed graft function following kidney transplant [28][36] Group 3: CIDP Insights - Results from an ADHERE post hoc analysis will highlight VYVGART Hytrulo's impact in treatment-naïve CIDP patients, supporting its earlier use in treatment paradigms [3][38] - Real-world insights will illustrate physician approaches to transitioning patients from intravenous immunoglobulin (IVIg) to VYVGART Hytrulo, aiming to enhance patient outcomes [3][38]

Core Viewpoint - Kamada (KMDA) is currently viewed as a better value opportunity compared to argenex SE (ARGX) based on various financial metrics and analyst outlooks [1][3][7] Valuation Metrics - KMDA has a forward P/E ratio of 19.55, while ARGX has a forward P/E of 31.09, indicating that KMDA is more attractively priced [5] - The PEG ratio for KMDA is 0.78, suggesting it is undervalued relative to its expected earnings growth, whereas ARGX has a PEG ratio of 1.27 [5] - KMDA's P/B ratio stands at 1.99, compared to ARGX's P/B of 6.33, further highlighting KMDA's superior valuation metrics [6] Analyst Outlook - KMDA holds a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision activity compared to ARGX, which has a Zacks Rank of 3 (Hold) [3][7] - The improving analyst outlook for KMDA suggests a stronger potential for value investors [3][7] Value Grades - KMDA has a Value grade of B, while ARGX has a Value grade of C, reflecting the overall assessment of their valuation metrics [6]

Summary of Argenx Conference Call Company Overview - **Company**: Argenx - **Event**: 46th Annual TD Cowen Healthcare Conference - **New CEO**: Karen Massey Key Points and Arguments Vision and Strategic Focus - Argenx 2.0 is a growth story focused on innovation, aiming to reach 50,000 patients by the end of the decade with 10 labeled indications and 5 molecules in late-stage development [4][5] - Short-term growth is expected from upcoming readouts in myositis and VYVGART for MMN, with plans for Sjögren's and CIDP in the future [5][6] Product Pipeline and Development - The FcRn strategy includes two next-generation molecules and an oral formulation, expanding the pipeline beyond FcRn [5][6] - Early-stage programs are being developed, including a recent deal with Tensegrity [6] VYVGART Performance - VYVGART has shown strong year-on-year growth, with a PDUFA date in May for seronegative MG patients and positive ocular MG data [23][24] - The company has reached $1 billion in sales, with CIDP accounting for approximately 35% of sales [26][27] - VYVGART is positioned as the number one prescribed biologic in MG, with a focus on removing friction for prescribers regarding antibody status [28][29] Market Dynamics and Competition - The company is aware of competition but believes VYVGART's safety profile and efficacy position it well against alternatives [59] - The market for MG treatments is evolving, with FcRns being used as first-line therapies, while C5 therapies are reserved for refractory patients [32][35] Myositis and Clinical Trials - The myositis trial is designed to assess efficacy across multiple subtypes, allowing flexibility in approval based on data [67][68] - The prevalence of DM and MMN is highlighted, with a focus on the unmet need in IMN [73][74] Sjögren's and Future Studies - The company is optimistic about the Sjögren's program, with plans for additional evidence generation following positive readouts [90][91] EMPA and CIDP Strategy - EMPA is positioned to transform outcomes for CIDP patients, with a focus on biomarker data and understanding patient heterogeneity [115][116] - The company is also exploring combination studies in MG, indicating a broad strategy for future indications [118][120] IgA Sweeper Development - The IgA sweeper is being developed for IgA nephropathy (IgAN) with plans for further indications like IgA vasculitis [124][129] Additional Important Insights - The company emphasizes the importance of treating ocular MG, as it significantly impacts patients' quality of life [51][52] - The competitive landscape is acknowledged, with a focus on differentiating VYVGART through its unique dosing options and safety profile [59][60] This summary encapsulates the key discussions and strategic directions presented during the conference call, highlighting Argenx's commitment to innovation and growth in the biotech sector.

FDA Approvals & Rejections - Armata Pharmaceuticals received FDA QIDP designation for AP-SA02, a bacteriophage-based candidate for complicated Staphylococcus aureus bacteremia, providing five years of market exclusivity and eligibility for Fast Track status [2][3] - Allurion Technologies gained FDA PMA approval for the Gastric Balloon System, a swallowable Smart Capsule that promotes fullness for about four months, targeting patients with a BMI of 30-40 [4][5] - Eton Pharmaceuticals' DESMODA oral solution was approved for managing central diabetes insipidus, with an expected peak annual sales of $30 million - $50 million [9][11] Deals - Gilead Sciences announced the acquisition of Arcellx for $115 per share, totaling an implied equity value of $7.8 billion, enhancing its position in cell therapy [12][13] - Vir Biotechnology entered a global collaboration with Astellas for VIR-5500, receiving $335 million in upfront payments and potential additional milestones of up to $1.37 billion [14][15][16] - Kairos Pharma signed a term sheet to acquire two oncology assets from Celyn Therapeutics, focusing on cancer therapeutics [17][18][20] Clinical Trials - Breakthroughs - MoonLake Immunotherapeutics reported positive Phase 2 trial results for Sonelokimab in axial spondyloarthritis, with 81% of patients achieving an ASAS40 response at Week 12 [21][22] - Novo Nordisk's CagriSema missed its primary endpoint in a Phase 3 trial against Zepbound, showing 23% weight loss compared to 25.5% with Tirzepatide [25][26][27] - Gossamer Bio's seralutinib missed the primary endpoint in the PROSERA Phase 3 study for pulmonary arterial hypertension, showing a placebo-adjusted improvement in Six-Minute Walk Distance [28][30][31] - Argenx's VYVGART met primary goals in the Phase 3 ADAPT OCULUS trial for ocular myasthenia gravis, demonstrating significant improvement in ocular scores [37][38][39]

Core Insights - Argenx SE reported strong fourth-quarter results, with earnings of $8.02 per share, exceeding the consensus estimate of $6.02, and sales increased from $761.2 million to $1.32 billion, surpassing the consensus estimate of $1.29 billion [1] - The company announced positive topline results from the Phase 3 ADAPT OCULUS study for VYVGART in adults with ocular myasthenia gravis [1] Financial Performance - Fourth-quarter earnings per share were $8.02, beating expectations [1] - Sales rose significantly from $761.2 million to $1.32 billion, exceeding analyst estimates [1] Product Development and Market Impact - VYVGART reached 19,000 patients globally, indicating successful market penetration [2] - The company expanded its impact in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) through the launch of a pre-filled syringe [2] - Progress was made in advancing the development pipeline towards key milestones [2] Stock Performance - Argenx shares closed at $771.53 following the earnings announcement [2] - Analysts adjusted their price targets for Argenx after the earnings report [2]